Previous Close | 13.97 |
Open | 13.70 |
Bid | 13.78 x 100 |
Ask | 14.08 x 100 |
Day's Range | 13.70 - 14.08 |
52 Week Range | 3.80 - 18.15 |
Volume | |
Avg. Volume | 109,352 |
Market Cap | 399.205M |
Beta (5Y Monthly) | 2.09 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.27 |
Earnings Date | May 08, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17.83 |
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may d
MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the Needham 23rd Annual Healthcare Conference, taking place virtually from April 8-11. Joel Becker, NeuroPace’s Chief Executive Officer, will provide a corporate presentation on Monday, April 8 at 3:45pm ET, and management will participate in one-on-one meetings with investors during
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript March 5, 2024 NeuroPace, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.33. NPCE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to NeuroPace’s Fourth Quarter […]